Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CytomX TherapeuticsCTMX -0.83%38 Days Sales Outstanding is 1,227.18 as of Jun. 2026, which is 5613% above its 10-year median of 21.48. GuruFocus rates CTMX with a GF Score™ of 38/100 and a GF Value™ of $0.15 (Significantly Overvalued). The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, CytomX Therapeutics ranks worse than 85.73% on this metric.
CytomX Therapeutics (NAS:CTMX) Days Sales Outstanding Explanation
For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.
CytomX Therapeutics Days Sales Outstanding Related Terms
CytomX Therapeutics Days Sales Outstanding Historical Data
* Premium members only.
The historical data trend for CytomX Therapeutics's Days Sales Outstanding can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CTMX vs GYRE, BBOT, TECX: Days Sales Outstanding Comparison
For the Biotechnology subindustry, CytomX Therapeutics's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CytomX Therapeutics Days Sales Outstanding vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CytomX Therapeutics's Days Sales Outstanding distribution charts can be found below:
* The bar in red indicates where CytomX Therapeutics's Days Sales Outstanding falls into.
CytomX Therapeutics Days Sales Outstanding Calculation
Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Days Sales Outstanding of 1,227.18 mean?
CytomX Therapeutics (CTMX) has a Days Sales Outstanding of 1,227.18 as of Jun. 2026. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CytomX Therapeutics and its competitors. This is 5613% above median its historical median of 21.48. Over the past decade, CytomX Therapeutics' Days Sales Outstanding has ranged from 0.75 to 174.11. According to the industry distribution chart, CytomX Therapeutics ranks #721 out of 841 companies in the Biotechnology industry, placing it in the top 85.7%.
Is CytomX Therapeutics' Days Sales Outstanding too high?
CytomX Therapeutics' current Days Sales Outstanding of 1,227.18 is 5613% above median its 10-year median of 21.48. Over the past 10 years, this metric has ranged from a low of 0.75 to a high of 174.11. The Biotechnology industry median Days Sales Outstanding is 68.98. CytomX Therapeutics' value of 1,227.18 is 1679% above this industry median. Based on the distribution chart, CytomX Therapeutics ranks #721 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CytomX Therapeutics has a GF Score™ of 38/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CytomX Therapeutics' Days Sales Outstanding compare to GYRE and BBOT?
According to the Biotechnology industry distribution chart, CytomX Therapeutics ranks #721 out of 841 companies for Days Sales Outstanding. This places CytomX Therapeutics in the lower half of its industry. The industry median Days Sales Outstanding is 68.98. CytomX Therapeutics' value of 1,227.18 is 1679% above this benchmark. Historically, CytomX Therapeutics' own Days Sales Outstanding has ranged from 0.75 to 174.11 over the past decade. While the company's 10-year median is 21.48 vs. the industry median of 68.98, CytomX Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Sales Outstanding for a Biotechnology company?
The median Days Sales Outstanding among Biotechnology companies is 68.98, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Days Sales Outstanding significantly above this median, while those in the bottom quartile fall well below. However, Days Sales Outstanding should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CytomX Therapeutics's current Days Sales Outstanding of 1,227.18 is 1679% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Sales Outstanding mean?
A high Days Sales Outstanding can signal that a stock is expensive relative to its fundamentals. Days sales outstanding represents the average amount of days a company takes to collect receivables. View historical data on CytomX Therapeutics and its competitors. For the Biotechnology industry, the median Days Sales Outstanding is 68.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CytomX Therapeutics's current Days Sales Outstanding is 1,227.18, which is 5613% above median its own 10-year median of 21.48. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CytomX Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, CytomX Therapeutics (CTMX) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.15, compared to a current price of $3.68 — trading 2352.7% above its estimated fair value. The current Days Sales Outstanding is 1,227.18, which is 5613% above median its 10-year median of 21.48 and 1679% above the Biotechnology industry median of 68.98. CytomX Therapeutics' overall GF Score™ is 38/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Sales Outstanding calculated?
Days Sales Outstanding is calculated from a company's financial statements. For CytomX Therapeutics (CTMX), the current Days Sales Outstanding is 1,227.18 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CytomX Therapeutics (CTMX) Overvalued in 2026?
Based on GuruFocus' analysis, CytomX Therapeutics stock appears to be overvalued.
The current stock price of $3.68 is trading 2352.7% above its estimated GF Value™ of $0.15.
GuruFocus considers CytomX Therapeutics to be Significantly Overvalued.
Key valuation signals for CTMX:
Days Sales Outstanding: 1,227.18 (5613% above median its 10-year median of 21.48)
GF Value™: $0.15 vs. price of $3.68 (2352.7% above fair value)
Industry Position: 1679% above the Biotechnology median (#721 of 841)
No single metric tells the full story. See the CTMX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CytomX Therapeutics Inc a clinical-stage, oncology-focused biopharmaceutical company developing novel, masked, conditionally activated biologics designed to be localized to the tumor microenvironment. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.
38GF Score
Get the complete analysis for CTMX
Days Sales Outstanding is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CTMX has been successfully added to your 
